Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis

PLoS ONE

Volumn 13, Issue 5, 2018, Pages

  Men, Peng ^a   Li, Xiao tong ^a   Tang, Hui lin ^a   Zhai, Suo di ^a  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; DAPAGLIFLOZIN; GLIBENCLAMIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIRAGLUTIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; PLACEBO; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN; ADAMANTANE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ADD ON THERAPY; BODY WEIGHT GAIN; COMBINATION DRUG THERAPY; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADAMANTANE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85047497182     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0197321     Document Type: Review

References (62)

1. Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017; 128:40–50. https://doi.org/10.1016/j.diabres.2017.03.024 PMID: 28437734.
2. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010; 87(3):293–301. https://doi.org/10.1016/j.diabres.2010.01.026 PMID: 20171754.
3. Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009; 23(4):479–86. https://doi.org/10.1016/j.beem.2009.03.004PMID: 19748065.
4. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006; 368(9548):1696–705. https://doi.org/10.1016/ S0140-6736(06)69705-5 PMID: 17098089.
5. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2016 executive summary. Endocr Pract. 2016; 22(1):84–113. https://doi.org/10.4158/EP151126.CS PMID: 26731084.
6. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012; 51(8):501–14. https://doi.org/10.2165/11632930-000000000-00000 PMID: 22686547.
7. Li H, Yang L, Tou CK, Patel CG, Zhao J. Pharmacokinetic study of saxagliptin in healthy Chinese subjects. Clin Drug Investig. 2012; 32(7):465–73. https://doi.org/10.2165/11598760-000000000-00000PMID: 22668067.
8. Li R, Wang R, Li H, Sun S, Zou M, Cheng G. Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2016; 32(6):460–9. https://doi.org/10.1002/dmrr.2731 PMID: 26433213.
9. Kim YG, Min SH, Hahn S, Oh TJ, Park KS, Cho YM. Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2016; 116:86–95. https://doi.org/10.1016/j.diabres.2016.03.011PMID: 27321321.
10. Foroutan N, Muratov S, Levine M. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis. Clin Invest Med. 2016; 39(2):E48–62. PMID: 27040861.
11. Elgendy IY, Mahmoud AN, Barakat AF, Elgendy AY, Saad M, Abuzaid A, et al. Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials. Am J Cardiovasc Drugs. 2017; 17(2):143–55. https://doi.org/10.1007/s40256-016-0208-x PMID: 27873238.
12. Sjöstrand M, Wei C, Cook W, Johnsson K, Pollack PS, Stahre C, et al. Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials. Diabetes Ther. 2017; 8(3):587–99. https://doi.org/10.1007/s13300-017-0261-8 PMID: 28432619.
13. Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg. 2011; 39(2):91–2. https://doi.org/10.1016/j.jcms.2010.11.001 PMID: 21145753.
14. Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012; 28(4):513–23. https://doi.org/10.1185/03007995.2012.665046 PMID: 22313154.
15. Barnett AH, Charbonnel B, Li J, Donovan M, Fleming D, Iqbal N. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clin Drug Investig. 2013; 33(10):707–17. https://doi.org/10.1007/s40261-013-0107-8 PMID: 23949898.
16. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009; 63(9):1395–406. https://doi.org/10.1111/j.1742-1241.2009.02143.x PMID: 19614786.
17. Chacra AR, Tan GH, Ravichandran S, List J, Chen R. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res. 2011; 8(2):150–9. https://doi.org/10.1177/1479164111404574 PMID: 21562067.
18. Chen Y, Liu X, Li Q, Ma J, Lv X, Guo L, et al. Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2018; 20(4):1044–1049. https://doi.org/10.1111/dom.13161 PMID: 29144061.
19. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes care. 2009; 32(9):1649–55. https://doi.org/10.2337/dc08-1984 PMID: 19478198.
20. Rosenstock J, Gross JL, Aguilar-Salinas C, Hissa M, Berglind N, Ravichandran S, et al. Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes. Diabet Med. 2013; 30(12):1472–6. https://doi.org/10.1111/dme.12267 PMID: 23802840.
21. Dou J, Ma J, Liu J, Wang C, Johnsson E, Yao H, et al. Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial. Diabetes Obes Metab. 2018; 20(3):590–598. https://doi.org/10.1111/dom.13117 PMID: 28926170.
22. Du J, Liang L, Fang H, Xu F, Li W, Shen L, et al. Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study). Diabetes Obes Metab. 2017; 19(11):1513–20. https://doi.org/10.1111/dom.12942 PMID: 28296055.
23. Fonseca V, Zhu T, Karyekar C, Hirshberg B. Adding saxagliptin to extended-release metformin vs. upti-trating metformin dosage. Diabetes Obes Metab. 2012; 14(4):365–71. https://doi.org/10.1111/j.14631326.2011.01553.x PMID: 22192246.
24. Frederich R, McNeill R, Berglind N, Fleming D, Chen R. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr. 2012; 4(1):36. https://doi.org/10.1186/1758-5996-4-36 PMID: 22828124.
25. Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010; 64(12):1619–31. https://doi.org/10.1111/j.1742-1241.2010.02510.x PMID: 20846286.
26. Göke B, Gallwitz B, Eriksson JG, Hellqvist A, Gause-Nilsson I. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract. 2013; 67(4):307–16. PMID: 23638466.
27. Hermans MP, Delibasi T, Farmer I, Lohm L, Maheux P, Piatti P, et al. Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. Curr Med Res Opin. 2012; 28(10):1635–45. https://doi.org/10.1185/03007995.2012. 735646 PMID: 23020253.
28. Hollander P, Li J, Allen E, Chen R; CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009; 94(12):4810–9. https://doi.org/10.1210/jc.2009-0550 PMID: 19864452.
29. Hollander PL, Li J, Frederich R, Allen E, Chen R; CV181013 Investigators. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2011; 8(2):125–35. https://doi.org/10.1177/1479164111404575 PMID: 21562064.
30. Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009; 11(6):611–22. https://doi.org/10.1111/j.1463-1326.2009.01056.x PMID: 19515181.
31. Pfutzner A, Paz-Pacheco E, Allen E, Frederich R, Chen R; CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011; 13(6):567–76. https://doi.org/10.1111/j.1463-1326.2011.01385.x PMID: 21342412.
32. Kadowaki T, Muto S, Ouchi Y, Shimazaki R, Seino Y. Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension. Expert Opin Pharmacother. 2017 Dec; 18(18):1903–1919. https://doi.org/10.1080/14656566.2017.1379990 PMID: 28901796.
33. Kumar KP, Jain SM, Tou C, Schützer K-M. Saxagliptin as initial therapy in treatment-naive Indian adults with type 2 diabetes mellitus inadequately controlled with diet and exercise alone: a randomized, double-blind, placebo-controlled, phase IIIb clinical study. Int J Diab Dev Ctries. 2014; 34(4):201–9.
34. Li CJ, Liu XJ, Bai L, Yu Q, Zhang QM, Yu P, et al. Efficacy and safety of vildagliptin, Saxagliptin or Sita-gliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol Metab Syndr. 2014; 6:69. https://doi.org/10.1186/1758-5996-6-69 PMID: 24917890.
35. Li CJ, Yu Q, Yu P, Zhang QM, Ding M, Liu XJ, et al. Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes. Exp Clin Endocrinol Diabetes. 2014; 122(8):469–76. https://doi.org/10.1055/s-0034-1374586 PMID: 24838155.
36. Lv C, Yu P, Zhou S, Li C, Lv L, Chen R. Efficacy and safety of saxagliptin combined metformin in newly diagnosed type 2 diabetes mellitus patients. Chin J Diab Mel. 2013; 5:759–62.
37. Matthaei S, Catrinoiu D, Celinski A, Ekholm E, Cook W, Hirshberg B, et al. Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes. Diabetes care. 2015; 38(11):2018–24. https://doi.org/10.2337/dc15-0811 PMID: 26324329.
38. Matthaei S, Aggarwal N, Garcia-Hernandez P, Iqbal N, Chen H, Johnsson E, et al. One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. Diabetes Obes Metab. 2016; 18(11):1128–33. https://doi.org/10.1111/dom.12741 PMID: 27403645.
39. Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J, et al. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes Obes Metab. 2014; 16(5):443–50. https://doi.org/10.1111/dom.12234 PMID: 24205943.
40. Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011; 13(6):523–32. https://doi.org/10.1111/j.1463-1326.2011.01382.x PMID: 21332627.
41. Nowicki M, Rychlik I, Haller H, Warren M, Suchower L, Gause-Nilsson I, et al. Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011; 65 (12):1230–9. https://doi.org/10.1111/j.1742-1241.2011.02812.x PMID: 21977965.
42. Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J. Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev. 2012; 28(3):268–75. https://doi.org/10.1002/dmrr.1306 PMID: 22081481.
43. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008; 10(5):376–86. https://doi.org/10.1111/j.1463-1326.2008.00876.x PMID: 18355324.
44. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009; 25(10):2401–11. https://doi.org/10.1185/03007990903178735 PMID: 19650754.
45. Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes care. 2015; 38(3):376–83. https://doi.org/10.2337/dc14-1142 PMID: 25352655.
46. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010; 26(7):540–9. https://doi.org/10.1002/dmrr.1114 PMID: 20824678.
47. Schernthaner G, Duran-Garcia S, Hanefeld M, Langslet G, Niskanen L, Ostgren CJ, et al. Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes Obes Metab. 2015; 17(7):630–8. https://doi.org/10.1111/dom.12461 PMID: 25761977.
48. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14):1317–26. https://doi.org/10.1056/NEJMoa1307684 PMID: 23992601.
49. White JL, Buchanan P, Li J, Frederich R. A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy. BMC Endocr Disord. 2014; 14:17. https://doi.org/10.1186/1472-6823-14-17 PMID: 24565221.
50. Xia C, Peng H, Zhang G. Clinical trial of saxagliptin combined metformin in newly diagnosed type 2 diabetes mellitus patients. Chinese Remedies & Clinics. 2014; 14(5):640–2.
51. Yang W, Pan CY, Tou C, Zhao J, Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract. 2011; 94(2):217–24. https://doi.org/10.1016/j.diabres.2011.07.035 PMID: 21871686.
52. Cahn A, Raz I, Mosenzon O, Leibowitz G, Yanuv I, Rozenberg A, et al. Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. Diabetes care. 2016; 39(8):1329–37. https://doi.org/10.2337/dc15-2763 PMID: 27222508.
53. Hirshberg B, Parker A, Edelberg H, Donovan M, Iqbal N. Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2014; 30(7):556–69. https://doi.org/10.1002/dmrr.2502 PMID: 24376173.
54. US food and drug administration. Safety Alerts for Human Medical Products: Diabetes Medications Containing Saxagliptin and Alogliptin: Drug Safety Communication—Risk of Heart Failure. 2015 [cited 2016 Aug 17]. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252
55. Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med. 2013; 125(3):7–20. https://doi.org/10.3810/pgm.2013.05.2659 PMID: 23748503.
56. Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res. 2012; 9 (2):109–16. https://doi.org/10.1177/1479164111436236 PMID: 22337893
57. Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012; 344:e1369. https://doi.org/10.1136/bmj.e1369 PMID: 22411919.
58. US Food and Drug Administration. FDA drug safety communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. 2015 [cited 2016 Aug 17]. http://www.fda.gov/Drugs/DrugSafety/ucm459579
59. Wang T, Wang F, Gou Z, Tang H, Li C, Shi L, et al. Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies. Diabetes Obes Metab. 2015; 17(1):32–41. https://doi.org/10.1111/dom.12386PMID: 25200423.
60. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014; 16(1):48–56. https://doi.org/10.1111/dom.12176 PMID: 23837679.
61. Giorda CB, Sacerdote C, Nada E, Marafetti L, Baldi I, Gnavi R. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine. 2015; 48 (2):461–71. https://doi.org/10.1007/s12020-014-0386-8 PMID: 25146552.
62. Yang W, Cai X, Han X, Ji L. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev.2016; 32(4):391–404. https://doi.org/10.1002/dmrr.2723 PMID: 26417956.